This database contains 22 studies, archived under the term: "Current Alzheimer Research"
Click here to filter this large number of results.
Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer’s disease: a pilot study
Carlsson, Cynthia M.,
Xu, Guofan,
Wen, Zhifei,
Barnet, Jodi H.,
Blazel, Hanna M.,
Chappell, Richard J.,
Stein, James H.,
Asthana, Sanjay,
Sager, Mark A.,
Alsop, David C.,
Rowley, Howard A.,
Fain, Sean B.,
Johnson, Sterling C.
Background/aims: Hypercholesterolemia in midlife increases risk for Alzheimer’s disease (AD) and contributes to cerebrovascular dysregulation – an early finding in preclinical AD pathology. Statins improve vascular reactivity, but it is unknown if they increase regional cerebral blood flow (CBF) in individuals at risk for AD.; Methods: In a randomized, controlled, double-blind pilot study, 16 asymptomatic […]
Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD
Egan, Michael,
Yaari, Roy,
Liu, Lian,
Ryan, Michael,
Peng, Yahong,
Lines, Christopher,
Michelson, David
We performed a clinical trial to evaluate the effects of the histamine subtype-3 receptor inverse agonist MK- 0249 on cognition in AD patients. Mild-to-moderate AD patients were randomized 1:1 to 4 weeks of double-blind daily treatment with oral MK-0249 5-mg or placebo. Pharmacokinetic and PET data suggested that MK-0249 5-mg daily would achieve approximately 85% […]
Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease
Maher-Edwards, G.,
Zvartau-Hind, M.,
Hunter, A. J.,
Gold, M.,
Hopton, G.,
Jacobs, G.,
Davy, M.,
Williams, P.
Background: This randomized, double-blind, placebo-controlled study investigated the efficacy and tolerability of the 5-HT6 receptor antagonist, SB-742457, in subjects with mild-to-moderate probable Alzheimer’s disease (AD).; Methods: Participating subjects had a Mini-Mental State Examination (MMSE) score of 12 to 26 after a 4-week, single-blind, placebo run-in phase, and were randomized (2:1:1:2) to receive placebo, SB-742457 5 […]
Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer’s disease
Straten, Guido,
Saur, Ralf,
Laske, Christoph,
Gasser, Thomas,
Annas, Peter,
Basun, Hans,
Leyhe, Thomas
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer’s disease (AD). One possible mechanism of action might be the induction of neurotrophins. Recently, we found a significant increase of brain-derived neurotrophic factor (BDNF) serum levels in AD patients treated with lithium and a significant decrease of ADAS Cog […]
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies
Harrington, C.,
Sawchak, S.,
Chiang, C.,
Davies, J.,
Donovan, C.,
Saunders, A. M.,
Irizarry, M.,
Jeter, B.,
Zvartau-Hind, M.,
van Dyck, C. H.,
Gold, M.
Introduction: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). An open-label extension study (REFLECT-4) assessed RSG XR long-term safety.; […]
Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil
Alvarez, X. Anton,
Cacabelos, R.,
Sampedro, C.,
Couceiro, V.,
Aleixandre, M.,
Vargas, M.,
Linares, C.,
Granizo, E.,
García-Fantini, M.,
Baurecht, W.,
Doppler, E.,
Moessler, H.
Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimer’s disease (AD). We compared the safety and efficacy of the neurotrophic compound Cerebrolysin (10 ml; n=64), donepezil (10 mg; n=66) and a combination of both treatments (n=67) in mild-to-moderate (mini-mental state examination-MMSE score 12-25) probable AD patients enrolled in […]
Safety of lumbar puncture procedures in patients with Alzheimer’s disease
Changes in cerebrospinal fluid (CSF) biomarkers are representative of biochemical changes in the brain. Collection of CSF by lumbar puncture (LP) is essential for biomarker analysis, which is important for research in neurodegenerative disorders. However, LP for research purposes has been controversial due to a reported high incidence of severe LP headache when using standard […]